Merck is spending $3 billion on an eye drug developer as it braces to lose a key cancer patent

Published on 29 May 2024 on Quartz

Pharma giant Merck said on Wednesday that it is acquiring the privately-held eye drug developer...

Read the rest of the article

Start tracking your investments with Statfolio

Merck and Co. (NYSE:MRK) has posted better-than-anticipated third-quarter profit thanks to solid...

Investing.com 31 Oct 2024

The company also reported light sales of HPV vaccine Gardasil and diabetes meds Januvia/Janumet.

Investor's Business Daily 31 Oct 2024

Merck’s stock swung between gains and losses in premarket action.

Market Watch 31 Oct 2024

Merck & Co. lowered the top end of its full-year sales guidance after demand for its HPV vaccine...

Bloomberg 31 Oct 2024

Merck on Thursday reported third-quarter revenue and adjusted earnings that topped expectations a...

CNBC 31 Oct 2024

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Disruptive analytics’s Substack by ...

Insider Monkey · via Yahoo Finance 30 Oct 2024

We recently compiled a list of the Jim Cramer’s Latest Game Plan: 20 Stocks to Watch. In this...

Insider Monkey · via Yahoo Finance 30 Oct 2024

Louge, professor emeritus of mechanical and aerospace engineering, credits the boulder with...

Cornell News Service 29 Oct 2024

Vera Therapeutics has shown the effect of atacicept on kidney function in patients with...

FierceBiotech 28 Oct 2024

On Monday, Merck & Co Inc (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) announced the initiation of ...

Benzinga · via Yahoo Finance 28 Oct 2024